Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Short-term Investments (2017 - 2025)

Lineage Cell Therapeutics' Short-term Investments history spans 9 years, with the latest figure at $15.0 million for Q4 2025.

  • For Q4 2025, Short-term Investments rose 643.55% year-over-year to $15.0 million; the TTM value through Dec 2025 reached $15.0 million, up 643.55%, while the annual FY2025 figure was $15.0 million, 643.55% up from the prior year.
  • Short-term Investments reached $15.0 million in Q4 2025 per LCTX's latest filing, up from $23000.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $46.5 million in Q4 2022 to a low of $17000.0 in Q2 2025.
  • Average Short-term Investments over 5 years is $9.8 million, with a median of $4.6 million recorded in 2021.
  • Peak YoY movement for Short-term Investments: tumbled 99.89% in 2023, then surged 3932.0% in 2024.
  • A 5-year view of Short-term Investments shows it stood at $2.6 million in 2021, then skyrocketed by 1678.29% to $46.5 million in 2022, then crashed by 99.89% to $50000.0 in 2023, then soared by 3932.0% to $2.0 million in 2024, then surged by 643.55% to $15.0 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Short-term Investments are $15.0 million (Q4 2025), $23000.0 (Q3 2025), and $17000.0 (Q2 2025).